

<p align="center"><b>Current Topics in GI Liver and Pathology-EM</b>  <b>Actual Time Schedule</b>  <b>December 28, 2023-December 28, 2026</b></p>		
<b>Time</b>	<b>Lecture</b>	<b>Speaker</b>
3.22 min	<b>Welcome and Conference Goals</b>	
51 min	<p><b>Title: Challenges in the diagnosis of IBD-associated dysplasia</b></p> <p>Objectives:</p> <ol style="list-style-type: none"> <li>1. Discuss the differential diagnosis between dysplasia and reactive non-neoplastic atypia</li> <li>2. Discuss the differential diagnosis between IBD-associated dysplasia and sporadic adenoma</li> <li>3. Discuss the histologic subtypes of IBD-associated dysplasia and their potential clinical implications</li> </ol>	<p><b>Cathy Changqing Ma, MD, PhD</b>  Associate Professor of Pathology and Immunology  Washington University St. Louis</p>
45 min	<p><b>Pearls in the diagnosis of colon cancer</b></p> <ol style="list-style-type: none"> <li>1. Discuss practical and clinically relevant issues in the diagnosis and staging of colorectal carcinoma</li> <li>2. Discuss features of colitis-associated colorectal carcinoma</li> </ol>	<p><b>Cathy Changqing Ma, MD, PhD</b>  Associate Professor of Pathology and Immunology  Washington University St. Louis</p>
29.48 min	<p>A GI Medical Oncologist’s Perspective – what are the biomarkers we care about?</p> <ul style="list-style-type: none"> <li>• Discuss the most important biomarkers in gastric cancer</li> <li>• Discuss new targetable options in biliary and colon cancer</li> </ul>	<p><b>Valerie Lee, MD</b>  Assistant Professor of Pathology  Johns Hopkins</p>
55 min	<p><b>Next generation cancer screening for the GI pathologist</b></p> <ol style="list-style-type: none"> <li>1. Understand the current performance and uncertainties of “liquid biopsy” multi-cancer early detection tests.</li> </ol>	<p><b>Benjamin L. Mazer, MD, MBA</b>  Assistant Professor of Pathology  Johns Hopkins</p>

	<p>2. Recognize the strengths and weaknesses of pancreatic cancer screening programs.</p> <p>3. Describe how artificial intelligence might play a future role in cancer screening.</p>	
42 min	<p><b>Post-Treatment Pathology: Pearls and Pitfalls</b></p> <p>1. Explain the clinical significance of response to neoadjuvant treatment.</p> <p>2. Describe how tumor regression is evaluated in upper and lower gastrointestinal carcinomas.</p> <p>3. Recognize diagnostic pitfalls associated with chemotherapy and radiation treatment.</p>	<p><b>Jacqueline Birkness-Gartman, M.D.</b>  Assistant Professor of Pathology  Johns Hopkins  Baltimore, MD</p>
34 min	<p><b>Sexually Transmitted Infections: Epidemiologic Trends and Digestive Manifestations</b></p> <p>1. Summarize national epidemiologic trends as they relate to sexually transmitted infections (STI)</p> <p>2. Identify population at risk of infection</p> <p>3. Recognize recently described patterns of inflammation associated with STI of the digestive tract</p>	<p><b>Lysandra Voltaggio, M.D.</b>  Associate Professor of Pathology  Johns Hopkins  Baltimore, MD</p>
57 min	<p>Title: Updates in Molecular Diagnostics for Malignancies of the Digestive Tract</p> <p>1. Discuss colon cancer screening</p> <p>2. Discuss the role and advances in circulating tumor DNA</p> <p>3. Discuss emerging targeted therapies</p>	<p><b>Jason Park, M.D., Ph.D.</b>  Associate Professor of Pathology  UT Southwestern  Dallas TX</p>
50 min	<p>Inflammatory Disorders of the Pancreas</p> <p>1. List the most common causes of acute and chronic pancreatitis</p>	<p><b>Elizabeth Thompson, M.D., Ph.D.</b>  Assistant Professor of Pathology  Johns Hopkins  Baltimore, MD</p>

	<p>2. Describe the diagnostic criteria for Type 1 (IgG4-related) and Type 2 autoimmune pancreatitis</p> <p>3. Define the most common molecular alterations associated with familial pancreatitis</p>	
59 min	<p>Hepatocellular Tumors – Virtual Sign Out</p> <ul style="list-style-type: none"> <li>• Understand the 3 main types of well differentiated hepatocellular tumors</li> <li>• Discuss the use of special stains and immunohistochemical stains in the work up of liver tumors</li> <li>• Integrate the clinical history and radiologic impression into the diagnostic approach to primary hepatocellular masses.</li> </ul>	<p><b>Robert Anders, M.D., Ph.D.</b> Associate Professor of Pathology Johns Hopkins Baltimore, MD</p>
47 min	<p>Title: “The horses and zebras of gastrointestinal lymphoma.”</p> <p>Objectives:</p> <ol style="list-style-type: none"> <li>1. Classify lymphomas based on morphology and immunophenotype</li> <li>2. Differentiate between indolent and aggressive lymphoproliferative disorders of the GI tract</li> <li>3. Discuss several ancillary tests that can aid in diagnosis</li> </ol>	<p><b>Laura M. Wake, MD</b> Assistant Professor of Pathology Johns Hopkins</p>
48 min	<p>Common Issues and Diagnostic challenges with Biliary Neoplasms</p> <ul style="list-style-type: none"> <li>• Review common issues with gallbladder carcinoma</li> <li>• Recognize challenges in small biopsies, frozen sections, and grossing of biliary neoplasms</li> <li>• Recognize mimickers of biliary neoplasms.</li> </ul>	<p><b>Kiyoko Oshima, M.D.</b> Associate Professor of Pathology Johns Hopkins Baltimore, MD</p>

49 min	<p>Title: Neuroendocrine tumors of the GI tract</p> <p>Objectives:</p> <ol style="list-style-type: none"> <li>4. Discuss various neuroendocrine tumors across the length of the GI tract</li> <li>5. Recognize potential pitfalls when evaluating for neuroendocrine tumors</li> </ol>	<p><b>Kevan Salimian, MD, PhD</b>  Assistant Professor of Pathology  Johns Hopkins  Baltimore, MD</p>
51 min	<p>Spindle Cell Lesions of the GI Tract: Just Like Real Estate, it's all about Location</p> <ul style="list-style-type: none"> <li>• To discuss the layers of the GI tract in which GI mesenchymal tumors tend to arise.</li> <li>• To discuss several types of GI mesenchymal tumors, with emphasis on their location and depth in the GI tract.</li> <li>• To distinguish various types of mucosal-based neural tumors</li> <li>• To consider syndromes that feature GI mesenchymal polyps.</li> </ul>	<p><b>Elizabeth Montgomery, M.D.</b>  Professor of Pathology  Vice Chair, Anatomic Pathology  University of Miami Miller School of Medicine Holtz Building  Miami, FL</p>
39 min	<p>Precancerous lesions of the pancreas. More than just PanINs!</p> <ol style="list-style-type: none"> <li>1. Understand the histologic features that distinguish pancreatic intraepithelial neoplasia (PanINs) and intraductal papillary mucinous neoplasms (IPMNs).</li> <li>2. Know the criteria used to classify the three main mass-forming precancerous neoplasms of the pancreas (Intraductal papillary mucinous neoplasms, intraductal oncocytic papillary neoplasms, and Intraductal tubulopapillary neoplasms).</li> <li>3. Appreciate the enormous three dimensional histologic and genetic</li> </ol>	<p><b>Ralph Hruban, M.D.</b>  Director of Pathology  Professor of Pathology and Oncology  Johns Hopkins  Baltimore MD</p>

	complexity of precancerous lesions of the pancreas.	
<b>1 hour and 35 minutes</b>		
<b>Q&amp;A Zoom Session Sunday Afternoon</b>		
	Dr. Montgomery	
	Dr. Hruban	
	Dr. Ma	
	Dr. Lee	
	Dr. Mazer	
	Dr. Birkness-Gartman	
	Dr. Voltaggio	
	Dr. Park	
	Dr. Thompson	
	Dr. Anders	
	Dr. Wake	
	Dr. Oshima	
	Dr. Salimian	